Trial reportPloS one2011
Granulocyte-colony stimulating factor (G-CSF) in stroke patients with concomitant vascular disease--a randomized controlled trial.
Trial report in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00298597 (Influence of G-CSF and EPO on Associative Learning and Motor Skills), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence of G-CSF and EPO on Associative Learning and Motor Skills
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Granulocyte-Colony Stimulating Factor (G-CSF) for stroke: an individual patient data meta-analysis.Scientific reports · 2016Pooled it
- Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke.The Cochrane database of systematic reviews · 2013Pooled it
- Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients.International journal of molecular sciences · 2016Trial
- Trial
- Revolutionizing Stroke Recovery: Unveiling the Promise of Stem Cell Therapy.Drug design, development and therapy · 2024Review
- Leptomeningeal anastomoses: Mechanisms of pial collateral remodeling in ischemic stroke.WIREs mechanisms of disease · 2022Review
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study.Brain sciences · 2021Article
- Cytokines-Biogenesis and Their Role in Human Breast Milk and Determination.International journal of molecular sciences · 2021Review
- Principles and requirements for stroke recovery science.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Review
- Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats.Experimental and therapeutic medicine · 2015Article
- Article
- Metabolic Syndrome and its Profound Effect on Prevalence of Ischemic Stroke.American medical student research journal · 2014Article
- The rise of cell therapy trials for stroke: review of published and registered studies.Stem cells and development · 2013Review
- Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke.The Yale journal of biology and medicine · 2012Review
- Stem cell therapy for cerebral ischemia: from basic science to clinical applications.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2012Review
- Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective.Journal of aging research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundG-CSF has been shown in animal models of stroke to promote functional and structural regeneration of the central nervous system. It thus might present a therapy to promote recovery in the chronic stage after stroke.
methodsHere, we assessed the safety and tolerability of G-CSF in chronic stroke patients with concomitant vascular disease, and explored efficacy data. 41 patients were studied in a double-blind, randomized approach to either receive 10 days of G-CSF (10 µg/kg body weight/day), or placebo. Main inclusion criteria were an ischemic infarct >4 months prior to inclusion, and white matter hyperintensities on MRI. Primary endpoint was number of adverse events. We also explored changes in hand motor function for activities of daily living, motor and verbal learning, and finger tapping speed, over the course of the study.
resultsAdverse events (AEs) were more frequent in the G-CSF group, but were generally graded mild or moderate and from the known side-effect spectrum of G-CSF. Leukocyte count rose after day 2 of G-CSF dosing, reached a maximum on day 8 (mean 42/nl), and returned to baseline 1 week after treatment cessation. No significant effect of treatment was detected for the primary efficacy endpoint, the test of hand motor function.
conclusionsThese results demonstrate the feasibility, safety and reasonable tolerability of subcutaneous G-CSF in chronic stroke patients. This study thus provides the basis to explore the efficacy of G-CSF in improving chronic stroke-related deficits.
trial registrationClinicalTrials.gov NCT00298597.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.